NCT00272961 - A Study Of Different Doses Of TBC3711 In Patients With Uncontrolled High Blood Pressure Already Taking Medications For High Blood Pressure. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions

Resistant Hypertension

Interventions

DRUG

Placebo

placebo tablet once daily for 12 weeks

DRUG

TBC3711

10 mg tablets once daily for 10 weeks

DRUG

TBC3711

50 mg tablet once daily for 10 weeks

DRUG

TBC3711

100 mg tablet once daily for 10 weeks

DRUG

TBC3711

200 mg tablet once daily for 10 weeks

Trial Locations (12)

12206

Pfizer Investigational Site, Albany

29681

Pfizer Investigational Site, Simpsonville

30309

Pfizer Investigational Site, Atlanta

30904

Pfizer Investigational Site, Augusta

36608

Pfizer Investigational Site, Mobile

38138

Pfizer Investigational Site, Germantown

71101

Pfizer Investigational Site, Shreveport

75006

Pfizer Investigational Site, Carroltown

75235

Pfizer Investigational Site, Dallas

98133

Pfizer Investigational Site, Seattle

35294-2041

Pfizer Investigational Site, Birmingham

73132-4904

Pfizer Investigational Site, Oklahoma City